OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.770
+0.320 (22.07%)
Apr 24, 2026, 4:00 PM EDT - Market closed
OS Therapies Employees
As of December 31, 2025, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$5,750,769
Market Cap
74.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - | 4 | 1 |
| Dec 31, 2024 | 5 | 1 | 25.00% | 4 | 1 |
| Mar 31, 2024 | 4 | 0 | - | 3 | 1 |
| Sep 30, 2023 | 4 | 0 | - | 3 | 1 |
| Mar 31, 2023 | 4 | - | - | 3 | 1 |
| Dec 31, 2022 | 4 | - | - | 3 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 142 |
| Pelthos Therapeutics | 92 |
| XBiotech | 85 |
| Fortress Biotech | 78 |
| Acrivon Therapeutics | 76 |
| ImmuCell | 73 |
| aTyr Pharma | 60 |
| PMV Pharmaceuticals | 54 |
OSTX News
- 10 days ago - OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes - Newsfile Corp
- 13 days ago - OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor - Newsfile Corp
- 18 days ago - OS Therapies Appoints Craig Eagle, MD as Strategic Advisor - Newsfile Corp
- 23 days ago - OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors - Newsfile Corp
- 26 days ago - OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update - Newsfile Corp
- 4 weeks ago - OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma - Newsfile Corp
- 4 weeks ago - OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma - Newsfile Corp
- 6 weeks ago - OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting - Newsfile Corp